The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways
Abstract
MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown. Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains. We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity. We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We detected a relatively smaller number of miRNAs in CSF, compared to other miRNA profiling studies19,28.”
From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [28]
In the citing paper
“Although the level of miR-9-5p was downregulated in AD brains and EVs from CSF [47,48,49]”
From MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease (2023) · cites this paper as [48]
In the citing paper
“Similar to miR-146a-5p, miR-132-3p was reported to be downregulated in AD in five independent studies [48,72,80,84] but up-regulated in AD in only one independent study [81].”
From MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease (2023) · cites this paper as [48]
In the citing paper
“Among these miRNAs, miR-146a-5p [50,70,73,74,83] and miR-132-3p [48,72,80,81,84] were reported to be dysregulated in six independent AD studies, respectively.”
From MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease (2023) · cites this paper as [48]
In the citing paper
“miR-125b-5p was upregulated in brains [36,48,50] and EVs from CSF of AD patients compared to HC [49,66].”
From MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease (2023) · cites this paper as [48]
In the citing paper
“Substantial recent evidence has demonstrated that microRNAs (miRNAs) are dysregulated already early on in AD pathology [2–7].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [4]
In the citing paper
“miR-92a-1-5p expression in AD brain is enhanced, while miR-501-3p expression is increased in both brain and serum of AD patients [41–43].”
From Neurodegenerative disease-associated microRNAs acting as signaling molecules modulate CNS neuron structure and viability (2025) · cites this paper as [43]
In the citing paper
“miR-92a-1-5p expression in AD brain is enhanced, while miR-501-3p expression is increased in both brain and serum of AD patients [41–43].”
From Neurodegenerative disease-associated microRNAs acting as signaling molecules modulate CNS neuron structure and viability (2025) · cites this paper as [43]
In the citing paper
“Both miRNAs are expressed in the human brain and are deregulated in AD [41–43, 54].”
From Neurodegenerative disease-associated microRNAs acting as signaling molecules modulate CNS neuron structure and viability (2025) · cites this paper as [43]
In the citing paper
“Many studies have detected extracellular/circulating miRNAs in biological fluids, such as plasma and serum (117, 118), cerebrospinal fluid (119), saliva (120), breast milk (121), urine, tears, colostrum, peritoneal fluid, bronchial lavage, seminal fluid (122), and ovarian follicular fluid (123).”
From Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018) · cites this paper as [119]
Citations
Cites
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Real-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,989
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
RAS Is Regulated by the let-7 MicroRNA Family
Johnson, S., Großhans, H., Shingara, J., Byrom, M., JARVIS, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,699
MicroRNAs Modulate Hematopoietic Lineage Differentiation
Chen, C.-Z., Li, L., Lodish, H. F., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1091903 · Cited by 3,257
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,153
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Cited by
Sorted by citations
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00402 · Cited by 5,287
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A. E., Crețoiu, D., Suciu, N., Creţoiu, S. M., & Voinea, S. C. (2020) · Cells · doi:10.3390/cells9020276 · Cited by 1,399
Cheng, L., Sharples, R. A., Scicluna, B. J., & Hill, A. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.23743 · Cited by 715
An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration
Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbuch, T., Eom, G., Hinz, M., Kaul, D., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3113 · Cited by 786
Circular RNA (circRNA) in Alzheimer’s disease (AD)
Lukiw, W. J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00307 · Cited by 636
“…or AD groups (p > 0.05, ANOVA); a dashed horizontal line at 1.0 indicates homeostatic (control) ciRS-7 levels for ease of comparison; ∗p < 0.001 (ANOVA). contribute to the down-regulation of selective miRNA-7-sensitive messenger RNA (mRNA) targets (Cogswell et al., 2008; unpublished observations).”
BackgroundInfluential
Metadata
- Authors
- Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., Prinjha, R. K., Richardson, J. C., Saunders, A. M., Roses, A. D., & Richards, C. A.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Asuragen (United States) (US)
- Molecular Cell Biology-RandD, Applied Biosystems Foster City, CA, USA
- GlaxoSmithKline (United Kingdom) (GB)
- Venue
- Journal of Alzheimer s Disease
- Publisher
- SAGE Publications
- Published
- 2008-05-09
- Volume
- 14
- Issue
- 1
- Pages
- 27-41
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W32204808
- Cited by
- 943
- References
- 65
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 28 · 2023: 35 · 2022: 50 · 2021: 78 · 2020: 62 · 2019: 60 · 2018: 69 · 2017: 65 · 2016: 64 · 2015: 83 · 2014: 71 · 2013: 74 · 2012: 50
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Institute on Aging (NIA AG05128)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, microRNA
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Brain, Cerebellum, Female, Frontal Lobe, Gene Expression Regulation, Genetic Markers, Hippocampus, Humans, Immunity, Innate, Insulin Resistance, Male, Middle Aged, Neurons, RNA, Messenger, Transfection, Biomarkers, Reverse Transcriptase Polymerase Chain Reaction, MicroRNAs, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
